This study is accepting new patients by invitation only

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

a study on Hematologic Malignancy Hematologic Neoplasms

Summary

Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.

Keywords

Solid and Hematological Malignancies, Hematologic Neoplasms, Axicabtagene ciloleucel, Brexucabtagene autoleucel, KITE-585, KITE-718, KITE-439, KITE-222, KITE-363, Axicabtagene Ciloleucel (KTE-C19 ), Brexucabtagene Autoleucel (KTE-X19)

Eligibility

You can join if…

  • The individual must have received an infusion of gene-modified cells in a completed Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or completed the post-treatment follow-up period in the parent study, as applicable
  • The individual must understand and voluntarily sign an Informed Consent Form (ICF) or an Informed Assent Form prior to any study-related assessments or procedures being conducted
  • In the investigator's judgment, the individual is willing and able to complete the protocol-required follow-up schedule and comply with the study requirements for participation

You CAN'T join if...

none

Locations

  • UCSF Medical Center
    San Francisco California 94143 United States
  • Stanford University
    Palo Alto California 94305 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Kite, A Gilead Company
Links
Gilead Clinical Trials Website
ID
NCT05041309
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 700 study participants
Last Updated